ProfileGDS5678 / 1444981_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 60% 59% 58% 60% 58% 58% 57% 58% 59% 60% 59% 58% 62% 59% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 13.6264760
GSM967853U87-EV human glioblastoma xenograft - Control 23.5174359
GSM967854U87-EV human glioblastoma xenograft - Control 33.516158
GSM967855U87-EV human glioblastoma xenograft - Control 43.5689260
GSM967856U87-EV human glioblastoma xenograft - Control 53.452358
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 13.6071158
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 23.5340657
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 33.4943458
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 43.515759
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 13.5554660
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 23.5183959
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 33.4737858
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 43.7307362
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 53.5226359